We are live on ! Find out more
PC

Polar Capital Portfolio holdings

AUM $13.5B
1-Year Est. Return 55.9%
This Fund
S&P 500
This Quarter Est. Return
+7.37%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$9.69B
AUM Growth
+$805M
Cap. Flow
+$420M
Cap. Flow %
4.33%
Top 10 Hldgs %
28.55%
Holding
286
New
47
Increased
108
Reduced
76
Closed
36

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$93.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$64.9M
3
AMZN icon
Amazon
AMZN
+$58.3M
4
SYK icon
Stryker
SYK
+$56.3M
5
PRAH
PRA Health Sciences, Inc.
PRAH
+$49.9M

Top Sells

Rank Stock Value
1
PEP icon
PepsiCo
PEP
+$77M
2
AMGN icon
Amgen
AMGN
+$72.2M
3
AET
Aetna Inc
AET
+$65.7M
4
CELG
Celgene Corp
CELG
+$54.3M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$52.8M

Sector Composition

Rank Sector Weight
1 Financials 21.51%
2 Healthcare 20.26%
3 Technology 19.08%
4 Communication Services 10.55%
5 Industrials 6.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
226
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.71M 0.02%
+37,500
New +$1.87M
ACAD icon
227
Acadia Pharmaceuticals
ACAD
$4.25B
$1.51M 0.02%
50,000
-25,000
-33% -$799K
NSTG
228
DELISTED
NanoString Technologies, Inc.
NSTG
$1.49M 0.02%
200,000
– –
SRPT icon
229
Sarepta Therapeutics
SRPT
$1.66B
$1.39M 0.01%
+25,000
New +$1.32M
HCM icon
230
HUTCHMED
HCM
$1.89B
$1.15M 0.01%
+30,000
New +$958K
VRNA
231
DELISTED
Verona Pharma
VRNA
$1.13M 0.01%
95,149
+19,232
+25% +$250K
SMMT icon
232
Summit Therapeutics
SMMT
$10.9B
$1.11M 0.01%
100,000
– –
RARX
233
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.06M 0.01%
125,000
-50,000
-29% -$615K
PTGX icon
234
Protagonist Therapeutics
PTGX
$8.75B
$1.04M 0.01%
50,000
-100,000
-67% -$1.77M
EFSC icon
235
Enterprise Financial Services Corp
EFSC
$2.41B
$824K 0.01%
+18,243
New +$798K
DESP
236
DELISTED
Despegar.com
DESP
$605K 0.01%
+22,000
New +$632K
MDB icon
237
MongoDB
MDB
$24B
$594K 0.01%
+20,000
New +$585K
HTT
238
High Templar Tech Ltd
HTT
$377M
$324K ﹤0.01%
+25,846
New +$498K
ACM icon
239
Aecom
ACM
$9.07B
– –
-71,655
Closed -$2.64M
ADAP
240
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-100,000
Closed -$819K
AGCO icon
241
AGCO
AGCO
$8.78B
– –
-371,657
Closed -$27.4M
AMGN icon
242
Amgen
AMGN
$203B
– –
-387,500
Closed -$72.2M
ARGX icon
243
argenx
ARGX
$57.4B
– –
-50,000
Closed -$1.12M
AXDX
244
DELISTED
Accelerate Diagnostics
AXDX
– –
-103,767
Closed -$23.3M
CRIS icon
245
Curis
CRIS
$9.53M
– –
-1,294
Closed -$3.86M
CRTO icon
246
Criteo
CRTO
$1.03B
– –
-336,314
Closed -$14M
DFS
247
DELISTED
Discover Financial Services
DFS
– –
-53,371
Closed -$3.44M
FIS icon
248
Fidelity National Information Services
FIS
$21.5B
– –
-297,270
Closed -$27.8M
FWONK icon
249
Liberty Media Series C
FWONK
$24.3B
– –
-274,854
Closed -$10.1M
HCA icon
250
HCA Healthcare
HCA
$84.8B
– –
-194,000
Closed -$15.4M
7 8 9
10
11

Similar funds

ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return
FS
Feinberg Stephen $2.61B AUM 15.12% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Polar Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Polar Capital held 286 positions worth $9.69B, up 9.1% from $8.89B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Polar Capital deployed $420M of net new capital in Q4 2017, opening 47 new positions and adding to 108 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 516,232 shares worth $65.6M.

By sector, the portfolio is most concentrated in Financials at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Aetna Inc, an estimated $65.7M trimmed.

  • Polar Capital's largest Q4 2017 buy was Alnylam Pharmaceuticals: 516,232 shares worth $65.6M.
  • Polar Capital added most to Microsoft in Q4 2017, an estimated $93.3M increase.
  • Polar Capital's biggest Q4 2017 reduction was Aetna Inc, cutting an estimated $65.7M.
  • Polar Capital fully exited PepsiCo in Q4 2017, selling an estimated $77M.
  • Polar Capital's ten largest holdings make up 29% of its $9.69B portfolio in Q4 2017.
  • Polar Capital opened 47 new positions and closed 36 in Q4 2017.
  • Polar Capital's portfolio value rose 9.1% quarter-over-quarter to $9.69B.

Based on Polar Capital's 13F filing for Q4 2017, filed 14 Feb 2018.